From fee for service to funding science

Multiple service providers have now launched their own venture funds or drug discovery arms. Are CDMOs/CROs the new Pharma?


MAUREEN COLEMANĀ | Chair | CN BioInnovations


THOMAS OGORKA | Chief Executive Officer | Orphan Reach
JENNY LAIRD | Vice President, Search & Evaluation Pain & Neurodegeneration | Eli Lilly and Company
CHRISTOPHE MULLER | Global Head Business Development | Evotec
DECLAN JONES | Vice President and Head of External Innovation (EI) and Scientific Licensing | Ferring Research Institute
RICHARD WEAVER | Founder and Managing Director | XenoGesis
CHARLES STEWARD | Patient Advocacy and Engagement Lead | Congenica